Pharma Sector’s Q4 Earnings To Be Under Pressure: Nirmal Bang
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
We expect Q4 FY21 earnings to be under pressure for most pharmaceutical companies in our coverage universe.
Domestic growth will be subdued due to Covid-19 and Q4 FY21 remains a seasonally weak quarter for most domestic names.
In addition, the U.S. market also did not witness any meaningful launches while overall prescriptions remained under pressure due to a renewed surge in Covid-19 cases there during the quarter.
Operational cost savings that have continued to aid pharma companies so far should reverse partially as travelling activities have begun to normalize.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.